Listing Category

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Robert Schumaker, Tennessee Cancer Specialists
Scroll to Top